Three products of the anticonvulsant are on back order from Acella Pharmaceuticals, and there is no expected resupply date. Mylan and Amneal Pharmaceuticals told ASHP their supply of gabapentin 250 milligram/5 milliliter oral solutions is available.
In its post, the ASHP clarified “gabapentin capsules are not affected by this shortage.”
As of May 2, the FDA has not reported a shortage of gabapentin.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.